High-Intensity Focused Ultrasound Surgery for Tumor Ablation: A Review of Current Applications.
Alessandro De MaioGiulia AlfieriMonica MattonePejman GhanouniAlessandro NapoliPublished in: Radiology. Imaging cancer (2023)
The management of cancer with alternative approaches is a matter of clinical interest worldwide. High-intensity focused ultrasound (HIFU) surgery is a noninvasive technique performed under US or MRI guidance. The most studied therapeutic uses of HIFU involve thermal tissue ablation, demonstrating both palliative and curative potential. However, concurrent mechanical bioeffects also provide opportunities in terms of augmented drug delivery and immunosensitization. The safety and efficacy of HIFU integration with current cancer treatment strategies are being actively investigated in managing primary and secondary tumors, including cancers of the breast, prostate, pancreas, liver, kidney, and bone. Current primary HIFU indications are pain palliation, complete ablation of localized earlystage tumors, or debulking of unresectable late-stage cancers. This review presents the latest HIFU applications, from investigational to clinically approved, in the field of tumor ablation. Keywords: Ultrasound, Ultrasound-High Intensity Focused (HIFU), Interventional-MSK, Interventional-Body, Oncology, Technology Assessment, Tumor Response, MR Imaging © RSNA, 2023.
Keyphrases
- high intensity
- resistance training
- magnetic resonance imaging
- minimally invasive
- papillary thyroid
- drug delivery
- radiofrequency ablation
- coronary artery bypass
- palliative care
- prostate cancer
- squamous cell
- catheter ablation
- contrast enhanced
- chronic pain
- clinical trial
- risk assessment
- neoadjuvant chemotherapy
- computed tomography
- randomized controlled trial
- squamous cell carcinoma
- body composition
- spinal cord injury
- mass spectrometry
- pain management
- magnetic resonance
- prognostic factors
- study protocol
- diffusion weighted imaging
- lymph node
- soft tissue
- contrast enhanced ultrasound
- advanced cancer
- phase ii
- postmenopausal women